Daily Bulletin

Men's Weekly

.

Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT05249127[1]) for patients with prostate...

Read more: Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

Business News

Manhari Founder, Maddy Gupta, urges businesses to capitalise on the rising value of metals

Old and unwanted equipment and business assets are often worth far more than they appear particularly those containing valuable metals. Precious metals, led by gold and silver reaching record highs...

Daily Bulletin - avatar Daily Bulletin

Qualities to Check in an NDIS Provider

Everyone wants to live life with independence and dignity. For people with disabilities, achieving this often requires the right support. This is where NDIS providers play an important role. These pro...

Daily Bulletin - avatar Daily Bulletin

How Thorough Component Inspections Protect Your Supply Chain from Costly Failures

In the modern world, where manufacturing has become highly interconnected, the weakest components of the supply chain can only make the chain as strong as it is. One defective component might cause ...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business